Cargando…
Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273
Heterologous vaccination against coronavirus disease 2019 (COVID-19) provides a rational strategy to rapidly increase vaccination coverage in many regions of the world. Although data regarding messenger RNA (mRNA) and ChAdOx1 vaccine combinations are available, there is limited information about the...
Ejemplares similares
-
Antibody durability at 1 year after Sputnik V vaccination
por: Sanchez, Lautaro, et al.
Publicado: (2022) -
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
por: Rearte, Analía, et al.
Publicado: (2022) -
Heterologous booster response after inactivated virus BBIBP-CorV vaccination in older people
por: Rouco, Santiago Oviedo, et al.
Publicado: (2022) -
Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose
por: Rossi, Andres H., et al.
Publicado: (2021) -
Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV
por: Mauas, Romina, et al.
Publicado: (2023)